Sana Biotechnology Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
SANA$2.43-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year Ended December 31, | ||||||
|---|---|---|---|---|---|---|
| 2023 · 2022 · 2021 | ||||||
| OPERATING ACTIVITIES: | ||||||
| Net loss | $(283,255) | $(269,476) | $(355,928) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
| Depreciation and impairment of long-lived assets | 24,557 | 15,625 | 11,070 | |||
| Stock-based compensation expense | 35,533 | 38,337 | 22,362 | |||
| Change in the estimated fair value of contingent consideration | (40,773) | (3,364) | 31,842 | |||
| Change in the estimated fair value of success payment liabilities | (8,208) | (81,518) | 26,031 | |||
| Non-cash expense for operating lease right-of-use assets | 13,265 | 12,106 | 6,844 | |||
| Other non-cash items, net | (13,312) | (9,302) | (3,076) | |||
| Changes in operating assets and liabilities: | ||||||
| Prepaid expenses and other assets | 8,143 | (5,988) | (861) | |||
| Operating lease right-of-use assets and liabilities | 10,959 | 1,562 | 5,088 | |||
| Accounts payable | 1,027 | 1,058 | (266) | |||
| Accrued expenses and other liabilities | (1,518) | 10,910 | 5,840 | |||
| Net cash used in operating activities | (253,582) | (290,050) | (251,054) | |||
| INVESTING ACTIVITIES: | ||||||
| Purchases of marketable securities | (157,744) | (78,688) | (491,387) | |||
| Proceeds from maturities of marketable securities | 349,788 | 310,126 | 280,025 | |||
| Purchases of property and equipment | (20,032) | (20,876) | (29,862) | |||
| Other investing activities | - | - | (4,574) | |||
| Net cash provided by (used in) investing activities | 172,012 | 210,562 | (245,798) | |||
| FINANCING ACTIVITIES: | ||||||
| Proceeds from initial public offering, net of issuance costs | - | - | 626,405 | |||
| Proceeds from issuance of common stock, net | 4,626 | 4,312 | 5,346 | |||
| Proceeds from issuance of common stock under at the market offering | 27,020 | 601 | - | |||
| Net cash provided by financing activities | 31,646 | 4,913 | 631,751 | |||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (49,924) | (74,575) | 134,899 | |||
| Cash, cash equivalents, and restricted cash at beginning of period | 187,273 | 261,848 | 126,949 | |||
| Cash, cash equivalents, and restricted cash at end of period | $137,349 | $187,273 | $261,848 | |||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||||||
| Cash and cash equivalents | $133,517 | $176,765 | $253,029 | |||
| Restricted cash | 3,832 | 6,100 | - | |||
| Long-term restricted cash | - | 4,408 | 8,819 | |||
| Total cash, cash equivalents, and restricted cash | $137,349 | $187,273 | $261,848 | |||
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||||||
| Operating lease right-of-use assets obtained in exchange for lease obligations | $8,984 | $21,073 | $39,996 | |||
| Purchases of property and equipment included in accounts payable and accrued liabilities | $9,471 | $1,234 | $3,015 | |||
| Cash received for tenant improvement allowances | $12,547 | $2,014 | $5,445 | |||
| Remeasurement of operating lease right-of-use asset for lease modification | $ | - | $(12,801) | $ | - | |
| Derecognition of operating lease right-of-use asset for lease termination | $(14,204) | $ | - | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.